Tyra Biosciences, Inc. expects a readout of its SURF302 trial results in September 2026 [1].
The outcome of the trial for dabogratinib is critical because it could validate the drug's FGFR3 profile. Such a result would provide a significant catalyst for the company's stock and validate its clinical approach to targeting specific protein mutations.
Analysts describe the upcoming data as a binary event. This means the stock price may react sharply depending on whether the results meet the expected benchmarks for FGFR3 activity [1]. If the readout is positive, it could support a bullish investment case for the biotech firm.
Market interest in the company has increased recently. On June 17, Oppenheimer initiated coverage of the company [2]. Additionally, Tyra has been listed as one of 10 most promising cancer stocks [2].
"Tyra Biosciences' dabogratinib has an upcoming readout in September 2026 that I think could validate its FGFR3 profile," a Seeking Alpha author said [1].
The SURF302 trial is designed to assess the efficacy and safety of dabogratinib. The company is focusing on the drug's ability to inhibit fibroblast growth factor receptor 3, which is often implicated in various cancers and genetic conditions. The September data will determine if the drug achieves the necessary activity to move forward in its development cycle [1].
“The upcoming SURF302 trial data for dabogratinib will test the drug's FGFR3 profile.”
The SURF302 readout represents a high-stakes milestone for Tyra Biosciences. In the biotech sector, binary bets occur when a company's valuation is heavily tied to a single clinical trial result. A successful validation of the FGFR3 profile would not only advance dabogratinib toward potential commercialization, but also solidify Tyra's position among top-tier oncology developers.
